Applications including "United States Pharmacopoeia"

LC042 - Analysis of Nicotinic acid,Pyridoxine Hydrochloride,Riboflavin,and Thiamine hydrochloride_Method3 (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin or Niacinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine_ Method3) -

LC InertSearch InertSustain C8
LC041 - Analysis of Nicotinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine hydrochloride_Method1 (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin or Niacinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine_ Method1) -

LC InertSearch InertSustain C18
LC040 - Analysis of Acetaminophen (Under the Condition of the USPNF2023 Issue 1, Acetaminophen, IMPURITIES, Limit of Free 4-Aminophenol) -

LC InertSearch InertSustainSwift C8
LC039 - Analysis of Acetaminophen (Under the Condition of the USPNF2023 Issue 1, Acetaminophen, ASSAY) -

LC InertSearch InertSustainSwift C8
LC036 - Analysis of Zonisamide (Under the Condition of USP41-NF36, Zonisamide Compounded Oral Suspension, ASSAY) -

LC InertSearch InertSustain C18
LC035 - Analysis of Zonisamide (Under the Condition of USP43-NF38, Zonisamide Capsules, ASSAY) -

LC InertSearch InertSustain C18
LC034 - Analysis of Zonisamide (Under the Condition of USP43-NF38, Zonisamide, ASSAY) -

LC InertSearch InertSustain C18
LC033 - Analysis of D‐Biotin (Under the Condition of USP43-NF38, Oil- and Water-Soluble Vitamins Minerals Tablets,BIOTIN_Method 3) -

LC InertSearch InertSustain C18
LC032 - Analysis of D‐Biotin (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,BIOTIN_Method 1) -

LC InertSearch InertSustain C8
LC031 - Analysis of D‐Biotin (Under the Condition of USP43-NF38, Biotin) -

LC InertSearch InertSustain C8
LC029 - Analysis of Riboflavin (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,RIBOFLAVIN_Method 2) -

LC InertSearch InertSustain C18
LC028 - Analysis of Pyridoxine hydrochloride (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,PYRIDOXINE HYDROCHLORIDE_Method 2) -

LC InertSearch InertSustain C18
LC027 - Analysis of Nicotinamide (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,NIACINAMIDE_Method 2) -

LC InertSearch InertSustain C18
LC026 - Analysis of Nicotinic acid (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin_Method 2) -

LC InertSearch InertSustain C18
LC023 - Analysis of Lansoprazole (Under the Condition of the USP41-NF36, Lansoprazole Compounded Oral Suspension, ASSAY) -

LC InertSearch InertSustain C18
LC021 - Analysis of Cyanocobalamin (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Cyanocobalamin_Method1) -

LC InertSearch Inertsil ODS-HL
LC016 - Analysis of Itraconazole (Under the Condition of USP-NF 2021 Issue 2, Itraconazole Capsules, ASSAY) -

LC InertSearch InertSustain C18
LC014 - Analysis of Itraconazole (Under the Condition of USP43-NF38, Itraconazole, ASSAY) -

LC InertSearch InertSustainSwift C18
LC012 - Analysis of Ethanol and Acetonitrile (Under the Condition for the Draft for USP, Tavaborole Topical Solution, Content of Alcohol) -

LC InertSearch Inertsil NH2
LC009 - Analysis of Ketotifen Fumarate (Under the Condition of USP-NF 2024 Issue 3, Ketotifen Fumarate, ASSAY) -

LC InertSearch Inertsil ODS-3
LC008 - Analysis of Ketotifen Fumarate (Under the Condition of USP-NF 2024 Issue 3, Ketotifen Fumarate, ASSAY) -

LC InertSearch InertSustain C18
LB991 - Analysis of Progestrone and Methyltestrone -

LC InertSearch Inertsil WP300 C18
LB985 - Analysis of Sumatriptan -

LC InertSearch Inertsil ODS-3
LB984 - Analysis of Sumatriptan -

LC InertSearch InertSustain AQ-C18
LB982 - Analysis of Ofloxacin -

LC InertSearch InertSustain C18
LB981 - Analysis of Ofloxacin -

LC InertSearch Inertsil WP300 C18
LB980 - Analysis of Desloratadine -

LC InertSearch InertSustain AQ-C18
LB961 - Analysis of Lidocaine -

LC InertSearch Insertsil WP300 C18
LB960 - Analysis of Lidocaine -

LC InertSearch Insertsil WP300 C18
LT147 - D-Mannitol Analysis Under USP Method -

LC Technical Note InertSphere Sugar-2 HAMILTON HC-75（Ca2+）
LT131 - HPLC Columns Compliant with Pharmacopoeia (USP, EP and JP） -

LC Technical Note
GT093 - Quantitative Test for Hydroxypropylcellulose with Reference to the Japanese Pharmacopoeia, 17th Edition -

GC Technical Note InertCap 1 InertCap Series
GT086 - Purity Test and Fatty Acid Content Ratio Test of Polysorbate 80 - Supplement II to the Japanese Pharmacopoeia, 16th Edition -

GC Technical Note InertCap Pure-WAX InertCap 5

Applications including "United States Pharmacopoeia"

LC042 - Analysis of Nicotinic acid,Pyridoxine Hydrochloride,Riboflavin,and Thiamine hydrochloride_Method3 (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin or Niacinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine_ Method3) -

LC041 - Analysis of Nicotinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine hydrochloride_Method1 (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin or Niacinamide,Pyridoxine Hydrochloride,Riboflavin,and Thiamine_ Method1) -

LC040 - Analysis of Acetaminophen (Under the Condition of the USPNF2023 Issue 1, Acetaminophen, IMPURITIES, Limit of Free 4-Aminophenol) -

LC039 - Analysis of Acetaminophen (Under the Condition of the USPNF2023 Issue 1, Acetaminophen, ASSAY) -

LC036 - Analysis of Zonisamide (Under the Condition of USP41-NF36, Zonisamide Compounded Oral Suspension, ASSAY) -

LC035 - Analysis of Zonisamide (Under the Condition of USP43-NF38, Zonisamide Capsules, ASSAY) -

LC034 - Analysis of Zonisamide (Under the Condition of USP43-NF38, Zonisamide, ASSAY) -

LC033 - Analysis of D‐Biotin (Under the Condition of USP43-NF38, Oil- and Water-Soluble Vitamins Minerals Tablets,BIOTIN_Method 3) -

LC032 - Analysis of D‐Biotin (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,BIOTIN_Method 1) -

LC031 - Analysis of D‐Biotin (Under the Condition of USP43-NF38, Biotin) -

LC029 - Analysis of Riboflavin (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,RIBOFLAVIN_Method 2) -

LC028 - Analysis of Pyridoxine hydrochloride (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,PYRIDOXINE HYDROCHLORIDE_Method 2) -

LC027 - Analysis of Nicotinamide (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,NIACINAMIDE_Method 2) -

LC026 - Analysis of Nicotinic acid (Under the Condition of USP41-NF36, Oil- and Water-Soluble Vitamins Capsules,Niacin_Method 2) -

LC023 - Analysis of Lansoprazole (Under the Condition of the USP41-NF36, Lansoprazole Compounded Oral Suspension, ASSAY) -

LC021 - Analysis of Cyanocobalamin (Under the Condition of USP4１-NF3６, Oil- and Water-Soluble Vitamins Capsules,Cyanocobalamin_Method1) -

LC016 - Analysis of Itraconazole (Under the Condition of USP-NF 2021 Issue 2, Itraconazole Capsules, ASSAY) -

LC014 - Analysis of Itraconazole (Under the Condition of USP43-NF38, Itraconazole, ASSAY) -

LC012 - Analysis of Ethanol and Acetonitrile (Under the Condition for the Draft for USP, Tavaborole Topical Solution, Content of Alcohol) -

LC009 - Analysis of Ketotifen Fumarate (Under the Condition of USP-NF 2024 Issue 3, Ketotifen Fumarate, ASSAY) -

LC008 - Analysis of Ketotifen Fumarate (Under the Condition of USP-NF 2024 Issue 3, Ketotifen Fumarate, ASSAY) -

LB991 - Analysis of Progestrone and Methyltestrone -

LB985 - Analysis of Sumatriptan -

LB984 - Analysis of Sumatriptan -

LB982 - Analysis of Ofloxacin -

LB981 - Analysis of Ofloxacin -

LB980 - Analysis of Desloratadine -

LB961 - Analysis of Lidocaine -

LB960 - Analysis of Lidocaine -

LT147 - D-Mannitol Analysis Under USP Method -

LT131 - HPLC Columns Compliant with Pharmacopoeia (USP, EP and JP） -

GT093 - Quantitative Test for Hydroxypropylcellulose with Reference to the Japanese Pharmacopoeia, 17th Edition -

GT086 - Purity Test and Fatty Acid Content Ratio Test of Polysorbate 80 - Supplement II to the Japanese Pharmacopoeia, 16th Edition -

Application Search